Literature DB >> 16469773

Gastric inhibitory polypeptide as an endogenous factor promoting new bone formation after food ingestion.

Katsushi Tsukiyama1, Yuichiro Yamada, Chizumi Yamada, Norio Harada, Yukiko Kawasaki, Masahito Ogura, Kazuhisa Bessho, Minqi Li, Norio Amizuka, Masahiro Sato, Nobuyuki Udagawa, Naoyuki Takahashi, Kiyoshi Tanaka, Yutaka Oiso, Yutaka Seino.   

Abstract

Calcium plays a fundamental role as second messenger in intracellular signaling and bone serves as the body's calcium reserve to tightly maintain blood calcium levels. Calcium in ingested meal is the main supply and inadequate calcium intake causes osteoporosis and bone fracture. Here, we describe a novel mechanism of how ingested calcium is deposited on bone. Meal ingestion elicits secretion of the gut hormone gastric inhibitory polypeptide (GIP) from endocrine K cells in the duodenum. Bone histomorphometrical analyses revealed that bone formation parameters in the mice lacking GIP receptor (GIPR(-/-)) were significantly lower than those of wild-type (GIPR(+/+)) mice, and that the number of osteoclasts, especially multinuclear osteoclasts, was significantly increased in GIPR(-/-) mice, indicating that GIPR(-/-) mice have high-turnover osteoporosis. In vitro examination showed the percentage of osteoblastic cells undergoing apoptosis to be significantly decreased in the presence of GIP. Because GIPR(-/-) mice exhibited an increased plasma calcium concentration after meal ingestion, GIP directly links calcium contained in meal to calcium deposition on bone.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16469773     DOI: 10.1210/me.2005-0187

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  52 in total

Review 1.  The hunger games of skeletal metabolism.

Authors:  Natalie K Y Wee; Paul A Baldock
Journal:  Bonekey Rep       Date:  2014-11-12

Review 2.  Diet: friend or foe of enteroendocrine cells--how it interacts with enteroendocrine cells.

Authors:  Sofia Moran-Ramos; Armando R Tovar; Nimbe Torres
Journal:  Adv Nutr       Date:  2012-01-05       Impact factor: 8.701

Review 3.  Targeting beta-cell mass in type 2 diabetes: promise and limitations of new drugs based on incretins.

Authors:  Marzieh Salehi; Benedikt A Aulinger; David A D'Alessio
Journal:  Endocr Rev       Date:  2008-02-21       Impact factor: 19.871

Review 4.  Influence of hormonal appetite and energy regulators on bone.

Authors:  Ee Cheng Khor; Natalie Kah Yun Wee; Paul A Baldock
Journal:  Curr Osteoporos Rep       Date:  2013-09       Impact factor: 5.096

Review 5.  Diabetes pharmacotherapy and effects on the musculoskeletal system.

Authors:  Evangelia Kalaitzoglou; John L Fowlkes; Iuliana Popescu; Kathryn M Thrailkill
Journal:  Diabetes Metab Res Rev       Date:  2018-12-20       Impact factor: 4.876

6.  Roux-en-Y gastric bypass surgery but not vertical sleeve gastrectomy decreases bone mass in male rats.

Authors:  Kerstin Stemmer; Maximilian Bielohuby; Bernadette E Grayson; Denovan P Begg; Adam P Chambers; Christina Neff; Stephen C Woods; Reinhold G Erben; Matthias H Tschöp; Martin Bidlingmaier; Thomas L Clemens; Randy J Seeley
Journal:  Endocrinology       Date:  2013-04-03       Impact factor: 4.736

7.  Double incretin receptor knock-out (DIRKO) mice present with alterations of trabecular and cortical micromorphology and bone strength.

Authors:  A Mieczkowska; S Mansur; B Bouvard; P R Flatt; B Thorens; N Irwin; D Chappard; G Mabilleau
Journal:  Osteoporos Int       Date:  2014-08-16       Impact factor: 4.507

Review 8.  The role of incretins in glucose homeostasis and diabetes treatment.

Authors:  Wook Kim; Josephine M Egan
Journal:  Pharmacol Rev       Date:  2008-12-12       Impact factor: 25.468

9.  Elevated circulating levels of an incretin hormone, glucagon-like peptide-1, are associated with metabolic components in high-risk patients with cardiovascular disease.

Authors:  Minako Yamaoka-Tojo; Taiki Tojo; Naonobu Takahira; Atsuhiko Matsunaga; Naoyoshi Aoyama; Takashi Masuda; Tohru Izumi
Journal:  Cardiovasc Diabetol       Date:  2010-05-14       Impact factor: 9.951

10.  Glucose-Dependent Insulinotropic Peptide Prevents Serum Deprivation-Induced Apoptosis in Human Bone Marrow-Derived Mesenchymal Stem Cells and Osteoblastic Cells.

Authors:  J L Berlier; I Kharroubi; J Zhang; A Dalla Valle; S Rigutto; M Mathieu; V Gangji; J Rasschaert
Journal:  Stem Cell Rev Rep       Date:  2015-12       Impact factor: 5.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.